Fortis Healthcare has appointed Ravi Rajagopal, non-executive independent director, as Chairman of the board with immediate effect.
Rajagopal was nominee of minority shareholders East Bridge Capital and Jupiter India Fund. They hold around 12% stake in the company. He is also the chairman of the audit committee of Vedanta. He was also the head of fiance and commercial at Ranbaxy Laboratories, between 1995-96.
Further, Fortis board is expected to shortlist qualified bidders today. The qualified bidders will be allowed 10 days window to conduct due-diligence on the company and submit binding bids on June 14.